Aprea Therapeutics (NasdaqCM:APRE) FY Conference Transcript

Aprea Therapeutics FY Conference Summary Company Overview - Company: Aprea Therapeutics (NasdaqCM: APRE) - Industry: Biopharmaceuticals, focusing on cancer treatment through small molecule inhibitors targeting genetic mutations [1][2] Core Points and Arguments - Focus on Precision Medicine: Aprea Therapeutics operates at the intersection of precision medicine and synthetic lethality, emphasizing a targeted approach to cancer treatment [2] - Pipeline Overview: The company is developing multiple programs, including: - ATR inhibitor - WE-one inhibitor (APR 1051) - Legacy p53 reactivator - An undisclosed target to be revealed later for intellectual property (IP) reasons [3][4] - Clinical Trials: - The WE-one inhibitor has progressed with the first patient enrolled and an open-label study ongoing. Data will be shared at an upcoming conference [4][5] - The ATR program has seen a shift from a once-daily (QD) to a twice-daily (BID) regimen due to pharmacokinetic properties, which has shown positive results [5][6] - Dosing and Safety: Initial maximum tolerated dose (MTD) was projected at 150 mg, but increased to 220 mg and 300 mg based on positive safety data, enhancing the therapeutic index [7][8] - Early Clinical Data: - Early signs of activity observed in the 70 mg cohort and stable disease in the 100 mg cohort, indicating potential efficacy as doses increase [9][10] - A case study of an 86-year-old patient showed improved response and stability after multiple lines of treatment, supporting the drug's potential [12][13] - Biomarker-Driven Approach: All programs are biomarker-driven, focusing on matching mutations with appropriate therapies, which is a key aspect of their personalized medicine strategy [15][16] Additional Important Information - Collaboration with MD Anderson: Aprea has a strong collaboration with MD Anderson for HPV positive head and neck cancer, generating promising preclinical data [14][15] - Combination Therapy Potential: Preclinical models indicate strong potential for both single-agent activity and combination therapies, with minimal side effects observed [17][19] - Financial Position: The company reported $16.5 million in cash, indicating a solid financial foundation to support ongoing and future programs [24] - Investment Opportunity: Aprea believes there is a good entry opportunity for investors, with upcoming catalysts expected to drive progress in their clinical programs [25] Conclusion Aprea Therapeutics is positioned as a promising player in the biopharmaceutical industry, focusing on innovative cancer treatments through a precision medicine approach. The ongoing clinical trials and strong financial backing present potential investment opportunities as the company continues to advance its pipeline.